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AbstrACt
Introduction Cognitive stimulation therapy (CST) is a 
psychosocial intervention for dementia. Group CST is 
effective in reducing cognitive decline and improving 
quality of life in patients with dementia. There is some 
evidence that individual CST (iCST) may be beneficial 
in reducing cognitive decline. People with intellectual 
disability (ID) have an increased risk of dementia. However, 
there are no published studies of CST in people with ID 
and dementia. This protocol describes the feasibility and 
acceptability of a randomised controlled trial of iCST 
delivered by carers to people with ID and dementia, 
compared with treatment as usual (TAU). The results of 
this study will inform the design of a future definitive 
randomised controlled trial.
Methods and analysis The iCST intervention has been 
adapted for this trial. Forty dyads (individuals with ID 
and their carer) will be randomised to either iCST or 
TAU. The manualised intervention comprises 40 iCST 
sessions delivered by a carer for 30 min, twice a week, 
over 20 weeks. The primary outcome will be process 
measures assessing the feasibility and acceptability of the 
intervention and trial procedures. The secondary outcome 
will be changes in the scores of outcome measures 
(cognition, functional ability and quality of life in individuals 
with ID, and caregiver burden, competence in managing 
dementia, and anxiety and depression in carers). Data 
will be collected at baseline, 11 weeks and at 21 weeks. 
A process evaluation will examine adherence to iCST and 
will include qualitative interviews with participants to 
identify aspects of the intervention that were or were not 
successful.
Ethics and dissemination The study has received ethical 
approval. The results of the study will be presented at 
conferences and submitted to a peer reviewed journal.
trial registration number ISRCTN18312288; Pre-results.
IntroduCtIon  
The incidence of dementia in older people 
with intellectual disabilities (IDs) is almost 
five times higher compared with the general 
population.1 In people with Down syndrome, 
the risk of dementia is greatly increased. One 
study found that over 97% of participants 
with Down Syndrome developed Alzheimer’s 
dementia over a 20-year period.2 Dementia is 
a significant cause of morbidity and mortality 
in people with ID.3 
There are several non-pharmacological 
interventions that aim to enhance cogni-
tion or reduce the impact of cognitive defi-
cits in individuals suffering from dementia, 
including cognitive training, cognitive reha-
bilitation, reminiscence therapy and cogni-
tive stimulation therapy (CST). Cognitive 
training involves guided practice on stan-
dardised tests that reflect specific cogni-
tive functions such as attention, memory 
and problem solving. Currently, there is no 
evidence for the effectiveness of cognitive 
training on patients on dementia.4 Cognitive 
rehabilitation is an approach to managing 
the impact of dementia related symptoms, 
such as memory loss, on activities of daily 
living. It involves setting specific goals and 
using strategies to learn new information and 
compensatory techniques. There is evidence 
from a small randomised controlled trial that 
cognitive rehabilitation therapy may improve 
goal performance and subjective memory 
ratings in participants with dementia.5 Remi-
niscence therapy involves the discussion of 
past activities and experiences using prompts 
and props such as photographs or objects. 
There is evidence that reminiscence therapy 
strengths and limitations of this study
 ► This is the first feasibility randomised controlled tri-
al on cognitive stimulation therapy which has been 
adapted for use in people with dementia and intel-
lectual disability (ID).
 ► The study is being led by researchers with expertise 
in carrying out trials in people with ID and trials of 
cognitive stimulation therapy.
 ► The findings of the study will need to be interpreted 
with caution due to this being a feasibility study.
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may improve communication but its effects on cognition 
are small.6
CST uses a range of methods to stimulate learning 
and memory, including errorless learning, reality orien-
tation and multisensory stimulation.7 8 Reality orienta-
tion involves presenting information about time, place 
and person to an individual in order to orient the indi-
vidual to his/her environment. It has been criticised for 
being too rigid and confrontational. CST employs the 
positive aspects of reality orientation, using a sensitive, 
respectful and person centred approach. There is consis-
tent evidence that CST improves cognitive functioning, 
quality of life, well-being, communication and social 
interaction in people with dementia in the general popu-
lation.9 Its effects are most marked on language skills 
such as naming, word finding and comprehension.10 The 
benefits of CST may arise from activation of neuronal 
networks associated with cognition such as memory and 
language.11 Most of the evidence is based on group CST, 
typically two sessions a week lasting 45 min, over a 7-week 
period.12 The intervention involves activities that include 
word association, categorisation, reminiscence, creative 
activities, number and word games and discussion of 
current affairs.
In the UK, the National Institute for Health and Clin-
ical Excellence guidelines13 recommend that people with 
mild/moderate dementia should be given the opportu-
nity to participate in a structured group CST programme. 
CST is cost-effective and has comparable efficacy to 
antidementia drugs.14
There have been no randomised controlled trials of 
CST or any of the aforementioned cognitive interven-
tions in people with dementia and ID. Given that CST 
has the most evidence for improving cognition in the 
general population, it may have similar effects in other 
populations such as people with ID. However, people 
with ID may respond differently to the intervention due 
to the presence of premorbid cognitive difficulties and 
differences in their cognitive profile, and therefore it is 
imperative that the impact of CST is examined within a 
randomised controlled trial.
To our knowledge, there has been only one pilot 
randomised controlled study of 25 participants with 
Down syndrome without dementia investigating the 
impact of group CST in improving cognition, adaptive 
functioning and quality of life, compared with treatment 
as usual (TAU).15 The study found that the interven-
tion significantly improved cognitive functioning in the 
group receiving CST pretreatment and post-treatment, 
and there was an improvement on quality of life scores 
at 3 months follow-up. However, when the treatment and 
control groups were compared, there were no differences 
in any of the outcomes post intervention and at 3 months. 
This finding is perhaps not surprising given that the 
participants did not have dementia and the sample size 
was also relatively small. However, the study did demon-
strate that CST could be adapted for use in people with 
ID.
In order for group CST to be successful, the groups 
should comprise individuals with a similar degree of 
cognitive impairment in order to ensure that participants 
are effectively engaged. Differences in baseline cogni-
tion in individuals with ID, coupled with possible sensory 
impairment, poses a challenge for recruitment and effec-
tive group work. Individual CST (iCST) may therefore be 
a more practical and acceptable option for people with ID 
and dementia. iCST involves participating in one-to-one 
activities with a carer. The iCST programme is based on 
similar principles to group CST and involves mental stim-
ulation, reminiscence and Reality Orientation. There are 
10 principles: mental stimulation; developing new ideas, 
thoughts and associations; focusing on opinions rather 
than facts; using reminiscence; using triggers to support 
memory; using a ‘person-centred’ approach; offering 
a choice of activities; enjoyment and fun; maximising 
potential; and strengthening the relationship by spending 
quality time together.16 iCST therefore promotes posi-
tive interactions between the carer and individual which 
could benefit their relationship and potentially enhance 
cognition.
There is some evidence for the effectiveness of iCST 
delivered by carers, for people with dementia in the 
general population. Typically, 75 sessions are admin-
istered by carers over a 25-week period (three sessions, 
each 30 min). A randomised controlled trial of individual 
reality orientation therapy in people with dementia 
receiving anticholinesterase inhibitors versus anticho-
linesterase inhibitors alone, found significant improve-
ments in cognition but not for behavioural or functional 
outcomes.17 A recent multicentre randomised controlled 
trial of manualised iCST delivered by family carers, 
compared with TAU, in 356 carers and individuals with 
dementia18 found that iCST did not improve cognition 
or quality of life for people with dementia and it did not 
improve carers’ physical or mental health. However, there 
was some improvement in the caregiving relationship and 
in carers’ health related quality of life. Possible reasons 
for the lack of differences in the treatment and control 
groups in relation to cognition and quality of life could 
be attributed to the poor therapy adherence rate. Only 
51% of the dyads completed more than 30 sessions out 
of 75 and 22% did not complete any sessions. Adherence 
analyses found that people with dementia who completed 
more sessions showed improved quality in the caregiving 
relationship and carers reported lower depressive symp-
toms at 26 weeks. Qualitative data suggested that people 
with dementia and their carers experienced better 
communication as a result of iCST.
No studies have examined the impact of iCST in people 
with ID and dementia. Given the lack of previous data and 
potential issues with adherence rates to the iCST inter-
vention, a feasibility study will help to address whether a 
full scale randomised controlled trial should be carried 
out in this population.
 o
n
 19 Decem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022136 on 9 December 2018. Downloaded from 
3Ali A, et al. BMJ Open 2018;8:e022136. doi:10.1136/bmjopen-2018-022136
Open access
Adapting the intervention for use in people with Id
We have modified and adapted the iCST manual in order 
to make it more suitable for use with people with ID and 
dementia. Where possible, we have retained the themes in 
the original manual but simplified the activities. However, 
some of the more complex activities were completely 
removed and substituted with alternative activities. An 
initial draft was developed with the input of a speech and 
language therapist. We then made further revisions to the 
manual following feedback from three group consulta-
tions with 12 health and social care professionals working 
with people with ID, 5 carers of people with ID and 5 indi-
viduals with ID. Selected activities from the manual were 
field-tested with five dyads (carer and individual with ID 
and dementia) who were asked to provide feedback on 
five activities each. Further changes to the manual were 
made based on the feedback.
AIMs And objECtIvEs
The aim of the study is to assess the feasibility of carrying 
out a future randomised controlled trial of iCST compared 
with TAU in people with ID and dementia. The primary 
objective of the study is to determine the feasibility of 
the intervention and study procedures, by assessing the 
recruitment rate and dropout rate of dyads (carer and 
individual with ID and dementia), the appropriateness of 
the outcome measures, adherence to the iCST interven-
tion and the acceptability of the intervention.
The secondary objective of the study is to examine the 
effects of iCST on the outcome measures which include 
measures of cognitive and adaptive functioning and 
quality of life in individuals with dementia and measures 
of carer burden, competence and anxiety and depression 
in carers. In addition, we aim to estimate the sample size 
of a full scale randomised controlled trial.
MEthods And AnAlysIs
design
This will be a single blind, feasibility randomised 
controlled trial of iCST delivered by carers (formal or 
informal) versus TAU for people with ID and dementia. 
TAU has been selected as the comparator arm as it 
reflects current practice. Forty dyads (one carer and one 
individual with ID and dementia) will be randomised to 
either the intervention group or control group (TAU). 
Each arm will have 20 dyads. The primary and secondary 
outcomes will be measured at baseline prior to randomis-
ation, at midpoint (11 weeks) and at the end of the inter-
vention (21 weeks).
sample size
A sample size of 40 has been selected for pragmatic 
reasons. Assuming a recruitment rate of 80% from partic-
ipants who are eligible, a sample size of 40 provides a 95% 
CI for the recruitment rate of 67.6%–92.4%. Assuming 
that 20% of participants drop out of the study, a sample 
size of 40 provides a 95% CI for the dropout rate of 
7.60%–32.40%.
Participants
Inclusion criteria
Participants will be over the age of 40. This age has been 
selected as people with Down syndrome are likely to present 
with dementia from the age of 40 onwards (cases in younger 
people are less common). They will have premorbid mild 
or moderate ID and have a confirmed diagnosis of mild 
or moderate dementia. The participants will be screened 
for the presence of dementia using the International Clas-
sification of Diseases, 10th version (ICD-10) criteria (taken 
from the Cambridge Examination of Mental Disorders of 
Older People with Down’s Syndrome and Others with Intel-
lectual Disabilities (CAMDEX-DS).19 The CAMDEX-DS 
does not screen for the severity of dementia which will be 
assessed using ICD-10 criteria and clinical judgement. Mild 
dementia is defined as memory loss affecting the learning 
of new material, and the cognitive difficulties do not signifi-
cantly impact on the person’s ability to live independently. 
As most people with ID require some support with daily 
living, in someone with mild dementia and ID, the level of 
decline in functioning would not be expected to be severe 
enough to require a significant increase in the support they 
are receiving. In a person with ID and moderate dementia, 
the memory loss is more marked, and there is a significant 
decline in the ability of the individual to carry out activities 
of daily living that they were able to do previously, resulting 
in greater dependence on others.
The participants will need to be able to communicate 
verbally and in English, and be able to participate in 
simple games. Participants taking dementia medication 
can continue to take these during the study.
Each individual will also need to have a carer such as 
a member of staff, family member or friend who knows 
the individual well and is willing to take part in the study. 
Carers will need to be over the age of 18, be able to speak 
English and provide consent to taking part.
Exclusion criteria
Participants will be excluded if they have severe dementia 
(indicated by a significant deterioration in cognitive 
functioning resulting in complete reliance on others and 
inability to recognise familiar people), significant phys-
ical illness or disability, visual or hearing impairment, or 
behavioural problems that could affect participation in 
the iCST sessions or during assessments.
Recruitment
Participants will be recruited from community learning 
(intellectual) disability teams based in England. Clini-
cians will be asked to screen their case load for potential 
participants (individuals with dementia and their carers) 
and will approach them to discuss the study. If they are 
interested in taking part, their details will be passed on 
to the trial research team who will contact the participant 
and their carer to arrange a face-to-face meeting in order 
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to assess eligibility. If they are eligible, and the individual 
and their carer agree to take part, then informed consent 
will be obtained from both the carer and the participant 
with dementia.
Participants’ capacity to consent to take part in the 
research will be assessed by the research assistant who will 
follow the guidelines stipulated in the Mental Capacity 
Act (2005). If the participant with dementia lacks the 
capacity to consent, a personal consultee (a relative or 
friend) will be consulted to consider the participant’s 
beliefs and wishes about taking part in the study, and they 
will need to sign the declaration form before the partici-
pant is included in the study. If a personal consultee is not 
available, then we will consider approaching a nominated 
consultee (a member of the clinical team not directly 
involved in the research) who will need to sign a decla-
ration form agreeing to the individual’s participation in 
the study.
We estimate that we will need to recruit four eligible 
dyads each month, over 10 months. If recruitment is 
anticipated to be slow, we will recruit from other centres 
if necessary.
Randomisation
Randomisation will occur after eligibility, consent and 
baseline assessments have been carried out. Randomisa-
tion will be undertaken centrally by the coordinating trial 
team using a web-based system called Sealed Envelope. An 
administrator, who is not involved in the study, will enter 
the patient’s trial ID into the web-based randomisation 
system (Sealed Envelope). This system will randomly allo-
cate the participant to either the intervention or control 
arm, and he/she will inform the participants of their 
allocation. Randomisation will be based on varying block 
sizes. Although participants cannot be blinded to their 
allocated group, the research assistant administering the 
questionnaires will be blind to the allocation group. Due 
to the risk of carers revealing the allocation group, carers 
will be reminded before the follow-up assessments not to 
divulge this information. At the end of the study, we will 
assess researcher blindness by asking them to guess the 
allocated group.
Intervention group
The intervention will comprise 40 sessions of iCST which 
will be delivered by carers using the modified manual. 
The number of sessions has been reduced to 40 from 
the original 75 sessions in an attempt to improve adher-
ence and acceptability of the intervention. Each carer will 
administer the activities within the manual two times a 
week for 30 min, over a period of 20 weeks. Each session 
will begin with discussion of the day, date, weather and 
location (5 min) followed by discussion of events in the 
news or current issues (5 min) and then the main activity 
(20 min). The activities are based around a different 
theme for each session and have been designed to be 
fun and engaging for the individual, as well as mentally 
stimulating. Activities include word and number games, 
discussion of current affairs and famous people, creative 
and physical activities and quizzes. Carers will be encour-
aged to make the activities person-centred and multisen-
sory and to tailor the activities to the ability and interests 
of the individual with ID. For example, pictures in the 
manual that the individual with ID is not familiar with 
could be replaced by pictures that are of interest or of 
relevance to them. Examples of how activities could be 
made easier or more challenging will be discussed.
The themes and activities within the manual are 
summarised in table 1.
Carer training and support
Carers will attend a half day training session on how to 
use the manual in either a group setting or will receive 
individual training at home, depending on their prefer-
ence, and this will be provided by the research team. They 
will receive a copy of the adapted manual which includes 
paper-based activities and additional materials for specific 
activities (eg, dominoes, activity Compact Disc, dice).
Carers will be asked to keep a record of their sessions 
(eg, the duration, activities completed, level of engage-
ment and enjoyment of activities by the individual and 
reasons for not competing the session) in a diary. In order 
to assess adherence to the manual, for each individual 
dyad, two sessions will be audio-taped (40 in total). A 
brief adherence measure will be developed for the study. 
If a carer is unable to continue the intervention (eg, due 
to poor health) then another carer can be substituted. 
In order to support the carers and to ensure continued 
momentum, the research team will contact carers at least 
once a month by phone and there will be regular contact 
by email. Home visits can also be carried out if needed. 
The intervention group will also have access to ‘usual 
care’ and therefore the intervention arm will be exam-
ining the additional effects of iCST.
Control group
The control group will continue to have access to their 
usual care which will include anticholinesterase inhibi-
tors, input from health professionals and any day activi-
ties. If they are interested, participants and carers in the 
control group will also be offered a copy of the manual 
and training in how to use it after the 20-week study 
period.
outcome measures
The primary outcome: feasibility measures
Recruitment rate
We will assess the proportion of people who are referred 
to the study and are eligible to take part, and the propor-
tion of people who are eligible and are willing to take part 
in the study. Reasons for refusing to take part in the study 
will be noted.
Retention and dropout rate
We will record the number of participants who completed 
assessments at each of the follow-up points and reasons 
for withdrawal/non-completion.
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Appropriateness of outcome measures
Missing data for each outcome measure will be analysed, 
as well as sensitivity of the outcome measure to change as 
a result of the intervention.
Adherence to the intervention and acceptability of the intervention
This will be assessed in a process evaluation using a mixed 
methods approach.
secondary outcome measures
Outcome measures will be recorded in both individ-
uals with dementia and their carer. at baseline, midway 
(11 weeks) and postintervention (21 weeks). See table 2 
for the schedule of assessments.
outcomes in individuals with dementia
Measures of cognition
Change in cognitive functioning will be measured by the 
Cambridge Cognitive Examination for older Adults with 
Down Syndrome (CAMCOG-DS) which will be adminis-
tered with the individual with dementia.19 It includes an 
assessment of orientation, language, attention, praxis and 
abstract thinking. It provides individual subscale scores 
and total scores. Higher scores indicate better ability.
The Modified Memory for Objects test from the Neuro-
psychological Assessment of Dementia in Intellectual 
Disabilities Battery20 will also be administered with individ-
uals with dementia. This assessment involves presenting 
seven every-day items to the individual and testing his/
her ability to recall an item that has been covered up. The 
maximum score is 7. Higher scores indicate better ability.
The Cognitive Scale for Down Syndrome (CSDS) 21 will 
be administered with carers. This measure has 61 items 
that have been validated in adults with Down syndrome 
but the items are relevant to people with ID in general. 
The scale includes items testing executive functioning, 
memory and language. Higher scores indicate better 
cognitive functioning.
Other outcome measures
Functional ability will be measured using the Alzhei-
mer’s Dementia Cooperative Study–Activities of Daily 
Living Inventory (ADCS-ADL).22 This will be adminis-
tered with the carer. This is a measure of the ability 
of the individual with dementia to carry out a range 
of daily activities. There are 23 items covering a range 
of areas such as feeding, bathing, grooming, preparing 
meals, use of household appliances and hobbies. The 
maximum score is 78. Higher scores indicate better 
ability. This measure has not been validated in people 
with ID but has been found to be sensitive to change 
after CST.23 Most of the items appear to be relevant to 
the ID population.
Quality of life will be assessed using the Quality of 
Life–Alzheimer’s Disease Scale (QOL-AD).24 This will 
be administered with the carer. This is a 13-item scale 
with items covering physical health, mood, family 
life and functioning. The maximum score is 52, with 
Table 1 Themes/activities within the manual
Session number Themes/activities Session number Themes/activities
1 My life 21 Associated words
2 Food 1 22 Orientation 1
3 Current affairs 23 Thinking cards
4 Number games 1 24 Household objects 1
5 Art discussion 1 25 Categorising objects 1
6 Cross words 26 Number games 3
7 Physical games 27 Sounds 2
8 Childhood toys 28 Jobs
9 Word games 1 29 Scenes 2
10 Sound games 1 30 Food 2
11 Using money 31 Art discussion 3
12 Travel 32 Household objects 2
13 Being creative 33 Physical games 2
14 Quiz games 1 34 Orientation 2
15 Clothes 35 Signs and symbols
16 Word games 2 36 Word games 3
17 Scenes 1 37 Memories of the past
18 Number games 2 38 Animals
19 Brands and products 39 Categorising objects 2
20 Art discussion 2 40 Quiz games 2
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higher scores indicating a better quality of life. There 
are currently no suitable measures for quality of life in 
people with ID and dementia. This measure has been 
used in studies of CST as a primary outcome measure 
and has been found to detect an improvement in 
quality of life.12 23
Carer outcomes
Care giving burden in both paid and informal carers will 
be assessed using the Care Giving Burden Scale (SCIDS).25 
Carers will be asked if the individual requires assistance in 
a range of areas, whether they have provided assistance 
in the last month and whether providing assistance has 
been stressful. There are three domains and each has a 
maximum score of 15.
The competence to look after someone with dementia 
will be assessed using the Sense of Competence in 
Dementia Care Staff Scale.26 This is a 17-item scale 
with four subscales (professionalism, building relation-
ships, care challenges and sustaining personhood). The 
maximum score is 68, with higher scores indicating more 
competence. Although this questionnaire was developed 
for care staff, the questions may also be relevant for family 
members. Minor modifications to the questions will 
need to be made to ensure that it is appropriate for use in 
both groups. This measure has been found to be sensitive 
to change following CST.27
The presence of an anxiety or depressive disorder in 
the carer will be assessed using the Hospital Anxiety and 
Depression Scale (HADS).28
Process evaluation
A process evaluation will be carried out, based on Medical 
Research Council guidance.29 The aim of the process 
evaluation will be to examine whether the different 
components of the intervention (eg, training of carers, 
monitoring visits) were consistently followed; the extent 
to which iCST is delivered as intended; the extent to 
which the intervention would need to be modified 
prior to a full trial in order to make it more acceptable 
to participants and understanding the perceived value, 
benefits and harm or unintended consequences of the 
intervention so that these are fully measured in the full 
trial. In order to carry out the process evaluation, a mixed 
methods approach employing qualitative and quantita-
tive approaches will be used.
Table 2 Schedule of assessments
Visit no
Screening 
(pretreatment 
assessment) Intervention phase Final visit Optional
1 2 3 4 5 6 7
Week number: 1 5 11 15 20
Window of flexibility for timing of visits: Eg, 
±7 days
Eg, 
±7 days
Eg, 
±7 days
Informed consent X
Medical history X
Eligibility confirmation (ICD-10 criteria) X
CAMCOG-DS X X X
Memory for objects test X X X
CSDS X X X
ADCS-ADL X X X
QOL-AD X X X
Caregiver Burden Scale X X X
HADS X X X
SCIDS Scale X X X
Training for carers X
Treatment adherence/monitoring visit X X
Trial evaluation questionnaire X
Semistructured interview X
Randomisation X
Adverse events review X X X X
Concomitant medication review X X X X
ADCS-ADL, Alzheimer’s Dementia Cooperative study–Activities of Daily Living Inventory; CAMCOG-DS, The Cambridge Cognitive 
Examination for older Adults with Down Syndrome; CSDS, Cognitive Scale for Down Syndrome; HADS, Hospital Anxiety and Depression 
Scale; QOL-AD, Quality of life–Alzheimer’s Disease Scale; SCIDS, Sense of Competence in Dementia Care Staff.
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Qualitative approach
At the end of the intervention, all the participants will be 
given a short questionnaire to complete about their expe-
rience and satisfaction in participating in the study and to 
provide feedback. Participants will be asked whether they 
thought the intervention was practical and acceptable, 
such as whether the length and number of sessions were 
appropriate. In addition, five dyads from the intervention 
group and five dyads from the control group will also be 
invited to participate in a semistructured interview where 
more detailed feedback will be obtained in relation to the 
acceptability of the intervention. We will enquire about 
what aspects of the intervention worked well or could be 
further improved and whether there were any positive 
or negative effects of the intervention on the individual 
with dementia. Participants will also be asked about their 
experience of the study processes (eg, randomisation) 
and assessments. The interviews will be audio-taped and 
transcribed verbatim. Transcripts will be analysed using 
thematic analysis supported by computer software (NVivo 
V.9). The analytic strategy will identify themes relating to 
the barriers and facilitators that will enable the successful 
implementation of the intervention.
Quantitative approach
Carer diaries will be examined to identify the number of 
sessions that were completed by each dyad and reasons 
for non-completion. We will calculate the proportion of 
dyads who were able to complete all the sessions, those 
who were able to complete 50% and those who did not 
complete any. We will examine the feedback for each 
activity to identify which themes and activities were likely 
to be completed or missed. The extent of participation of 
the individuals in the sessions will also be examined (eg, 
full or partial participation). The quality of the delivery 
of the iCST intervention will also be assessed by audio-
taping two sessions carried out by each dyad (40 in total) 
and these will be rated on the extent to which they follow 
the manual.
One of the major challenges will be changes in paid 
carers or periods where no carer may be available due 
to illness or annual leave during the course of the inter-
vention. We will examine the frequency of changes 
in carers and the number of sessions missed due to 
unavailability of carers. We will examine whether there 
are differences in adherence rates between paid and 
family carers.
Incentives
In both arms of the study, the carers and participants with 
dementia will receive a £10 gift voucher for completing 
each follow-up assessment (at 11 weeks and 21 weeks; £20 
in total). Carers in the intervention arm will receive an 
additional £10 gift voucher for competing each audio-
taped session (£20 total). The participants who take part 
in the postintervention interviews will also receive a £10 
gift voucher each.
Patient and public involvement
Patients and the public were not involved in the design of 
the study and will not be involved in the conduct of the 
study. The findings of the study will be disseminated to the 
study participants in the form or an accessible newsletter.
statistical analysis
The study sample will be analysed using descriptive statis-
tics. Data on recruitment will be recorded and examined. 
This will include information on how many participants 
were approached and agreed to be screened; how many 
met the eligibility criteria and agreed to take part and how 
many completed the study, or dropped out. This infor-
mation will be presented in a Consolidated Standards of 
Reporting Trials (CONSORT) diagram describing the 
flow of participants through the study (see figure 1).
The baseline clinical and demographic characteristics 
of participants in both arms of the study will be compared 
descriptively. Descriptive statistics (mean and SD), and the 
proportion of participants who competed the measures, 
will be reported for each outcome at baseline, 11 weeks 
and 21 weeks which will provide data on determining the 
most appropriate outcome for a future trial.
A linear regression model adjusting for baseline scores 
will be used to estimate the effect of iCST on each of 
the outcome variables. The results will be presented as 
estimates with 95% CIs. The analysis will be based on 
intention to treat and will be exploratory due to the 
small sample size. Based on this analysis, an appropriate 
primary outcome will be identified and will be used to 
estimate the sample size for a future RCT.
Criteria for progression to a full trial
We will consider a full trial if the following criteria are 
met:
1. If we are able to achieve at least 70% of our recruit-
ment target of 40 (28 dyads or more).
2. If 75% of the dyads in the intervention arm complete 
at least half the number of sessions (20 sessions out of 
40). If less than 50% of the dyads complete half the 
sessions, the intervention is likely to be ineffective16
3. The dropout rate of dyads in the entire study is less 
than 30%.
4. The intervention and trial procedures are considered 
to be acceptable by study participants. 
If the study recruits 50-69% of the target, 50-74% complete 
at least half the number of sessions and the drop out rate 
is 21-30% we will consider whether measures can be imple-
mented in order to improve these outcomes and this will 
inform our decision to progress to a full trial. If the recruit-
ment rate is below 50% and less than 50% complete half the 
sessions and the drop out rate is more than 30%, we will not 
consider running a full trial.
EthICs And dIssEMInAtIon
research governance and trial sponsorship
Any amendments to the trial protocol, participant infor-
mation sheets, consent forms, General Practitioner letters 
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and any submitted supporting documents will not be 
implemented prior to receipt of the required approvals. 
Paper-based data that are collected will be stored securely 
in locked filing cabinets in locked offices at University 
College London. Participants will be given participant 
identification numbers, and participant identifiable data 
will be anonymised and password protected. The results 
of the study will be published in peer-reviewed journals 
and presented at conferences.
study time line
The trial is anticipated to last a duration of 18 months. 
There will be 10 months of recruitment and a further five 
months for follow up assessments. There will be three 
months to complete the process evaluation, to analyse the 
results and write up the study findings.
dIsCussIon
Dementia is more common in people with ID but the 
evidence base for interventions in dementia in people with 
ID is very limited. iCST may be particularly useful in people 
with ID due to the person-centred nature of the intervention, 
making it easier to tailor activities based on the individual’s 
preference and the availability of paid carers who may be 
able to deliver the intervention as part of their caring role. 
To our knowledge, this is the first feasibility study of iCST in 
people with ID and dementia. The study will provide infor-
mation about whether this treatment is feasible and accept-
able for people with ID.
A key challenge that may arise from the study is adherence 
to the intervention.18 By reducing the number of sessions 
to be delivered by the carer from 70 to 40, we hope to mini-
mise the burden on carers delivering the intervention. 
Previous studies on iCST have been carried out using only 
family carers, whereas we intend to include paid carers. This 
may have an advantage in that paid carers are more likely to 
have dedicated time that they can use to carry out the iCST 
sessions (eg, as part of a key work session), and they may value 
the structured nature of the intervention and appreciate the 
therapeutic value of the intervention in enhancing commu-
nication and interaction with the individual. However, not 
all individuals will have access to one-to-one support from a 
paid carer, even if they live in a care home, and paid carers 
may also experience stress as a consequence of caring for 
Figure 1 Trial flow chart illustrating the flow of participants through the study from referral through to analysis of data. The 
number of participants who are referred and are eligible will be recorded as will the number of people who are eligible and agree 
to be randomised. Reasons for participant withdrawal/dropout will be recorded. iCST, individual cognitive stimulation therapy; 
TAU, treatment as usual. 
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someone with dementia.30 Other challenges include the 
frequent changes and turnover of staff which could affect 
the delivery of the intervention and the value of having carer 
outcome measures.
If the study meets the prespecified progression criteria, 
we will apply for funding to conduct a full-scale RCT in 
order to examine the effectiveness of iCST compared 
with TAU. This study could lead to changes in health 
policy, including improved access to CST for people with 
ID and dementia.
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